Molina Healthcare, Inc. (MOH) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Molina Healthcare’s revenue went from $17.8B in fiscal 2016 to $45.4B in fiscal 2025, growth of about 11.0% a year.
Net income in fiscal 2025 was $472M, a net margin of 1.0%; the best year in this period was 2024 with $1.2B.
Over the twelve months to September 30, 2026, revenue was $44.1B and net income -$48M.
Free cash flow was -$636M in fiscal 2025 and positive in 8 of the 10 years shown.
The diluted share count fell 6% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.1B | $45.4B | $40.6B | $34.1B | $32.0B | $27.8B | $19.4B | $16.8B | $18.9B | $19.9B | $17.8B |
| Gross profit | $5.6B | $5.9B | $6.2B | $5.4B | $4.8B | $4.1B | $2.5B | $2.3B | $2.5B | $1.8B | $1.7B |
| Operating income | $172M | $781M | $1.7B | $1.6B | $1.2B | $1.0B | $1.1B | $1.0B | $1.1B | -$555M | $306M |
| Net income | -$48M | $472M | $1.2B | $1.1B | $792M | $659M | $673M | $737M | $707M | -$512M | $52M |
| EPS (diluted) | $-0.68 | $8.92 | $20.42 | $18.77 | $13.55 | $11.25 | $11.23 | $11.47 | $10.61 | $-9.07 | $0.92 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +11.8% | +19.3% | +6.6% | +15.1% | +43.0% | +15.4% | −10.9% | −5.0% | +11.8% | +25.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $331M | -$535M | $644M | $1.7B | $773M | $2.1B | $1.9B | $434M | -$314M | $804M | $673M |
| Capital spending | -$93M | -$101M | -$100M | -$84M | -$91M | -$77M | -$74M | -$57M | -$30M | -$86M | -$176M |
| Free cash flow | $238M | -$636M | $544M | $1.6B | $682M | $2.0B | $1.8B | $377M | -$344M | $718M | $497M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $0 | $1.0B | $1.0B | $0 | $400M | $128M | $606M | $47M | $0 | $0 | — |
| Stock-based pay | $105M | $47M | $116M | $115M | $103M | $72M | $57M | $39M | $27M | $46M | $26M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $8.3B | $9.0B | $9.1B | $7.5B | $7.6B | $6.0B | $4.4B | $4.5B | $5.7B | $4.6B |
| Debt | — | $3.8B | $3.0B | $2.3B | $2.3B | $2.3B | $2.2B | $1.3B | $1.5B | $2.2B | $1.6B |
| Equity | — | $4.1B | $4.5B | $4.2B | $3.0B | $2.6B | $2.1B | $2.0B | $1.6B | $1.3B | $1.6B |
| Total assets | — | $15.6B | $15.6B | $14.9B | $12.3B | $12.2B | $9.5B | $6.8B | $7.2B | $8.5B | $7.4B |
| Shares (diluted) | 52M | 53M | 58M | 58M | 58M | 59M | 60M | 64M | 67M | 56M | 56M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 12.6% | 13.1% | 15.3% | 15.9% | 15.0% | 14.6% | 12.8% | 13.7% | 13.3% | 9.1% | 9.7% |
| Operating margin | 0.4% | 1.7% | 4.2% | 4.6% | 3.7% | 3.7% | 5.5% | 6.2% | 6.0% | -2.8% | 1.7% |
| Net margin | -0.1% | 1.0% | 2.9% | 3.2% | 2.5% | 2.4% | 3.5% | 4.4% | 3.7% | -2.6% | 0.3% |
| FCF margin | 0.5% | -1.4% | 1.3% | 4.6% | 2.1% | 7.3% | 9.4% | 2.2% | -1.8% | 3.6% | 2.8% |
| ROIC | — | 7.9% | 16.8% | 18.0% | 16.6% | 15.5% | 17.5% | 24.0% | 25.8% | -13.2% | 7.3% |
| ROE | — | 11.6% | 26.2% | 25.9% | 26.7% | 25.1% | 32.1% | 37.6% | 42.9% | -38.3% | 3.1% |
Frequently asked questions
What is Molina Healthcare’s annual revenue?
$45.4B in fiscal 2025 and $44.1B over the twelve months to September 30, 2026.
How much profit does Molina Healthcare make?
Net income was $472M in fiscal 2025 (net margin 1.0%).
Is Molina Healthcare’s revenue growing?
Yes: revenue rose 11.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.